

Clinical Trial Protocol

Iranian Registry of Clinical Trials

10 Jun 2026

Comparison of letrozole and clomiphene in mild protocol among infertile poor responders

Protocol summary

Study aim

The aim of present study was to compare the efficacy of letrozole and clomiphene citrate for mild ovarian stimulation on ART outcomes in poor responder women.

Design

phase 2 of clinical trial. a computer-generated list of random numbers was used for patient classification

Settings and conduct

It is a randomized clinical trial, No blinding. Yazd Infertility Research Center was conducted.

Participants/Inclusion and exclusion criteria

women included in this study who had one or more previous failed ART cycle in which three or fewer oocytes were been retrieved and had serum E2 levels ≤ 500 pg/ml on the day of hCG administration. The exclusion criteria were: BMI > 30 kg/m², Endocrine or metabolic disorders, History of ovarian surgery, Severe endometriosis, Azoospermia in male partner, FSH > 15 m IU/ml

Intervention groups

All women received oral contraceptive for 21 days which started on the first day of previous cycle. In group I, stimulation was started by administration of clomiphene citrate 100 mg daily from day 3 of menstruation cycle until day 7 of the cycle. Patients in group II received letrozole from day 3 of the cycle 5mg /day for 5 days. In both groups, gonadotropins stimulation with hMG 225-300 IU daily was started from day 5 of cycle. Patient was monitored by serial vaginal ultrasonography and measurement of serum E2 levels. As the dominant follicle reached to 14mm in mean diameter, 0.25 mg/day GnRH antagonist. When at least two follicles with a mean diameter of 18 mm were observed, 10000 IU hCG (Pregnyl, Organon, Netherlands) was administrated.

Main outcome variables

Chemical pregnancy was defined by positive β -hCG, 12 days after embryos transfer. Clinical pregnancy was identified as observation of fetal heart activity by transvaginal ultrasonography.

General information

Reason for update

Updating the trial according to the correct date of ethics code

Acronym

IRCT registration information

IRCT registration number: **IRCT201107146420N3**

Registration date: **2011-08-10, 1390/05/19**

Registration timing: **retrospective**

Last update: **2021-09-07, 1400/06/16**

Update count: **3**

Registration date

2011-08-10, 1390/05/19

Registrant information

Name

Maryam Eftekhar

Name of organization / entity

Yazd Research and Clinical Center for Infertility

Country

Iran (Islamic Republic of)

Phone

+98 35182470856

Email address

eftekhar@ssu.ac.ir

Recruitment status

Recruitment complete

Funding source

Research and Clinical Center for infertility, Shahid Sadoughi University of Medical Sciences

Expected recruitment start date

2009-01-01, 1387/10/12

Expected recruitment end date

2011-08-01, 1390/05/10

Actual recruitment start date

2009-03-01, 1387/12/11

Actual recruitment end date

2011-05-30, 1390/03/09
Trial completion date
2011-10-30, 1390/08/08

Scientific title
Comparison of letrozole and clomiphen in mild protocol among infertile poor responders

Public title
Comparison of letrozole and clomiphen in mild protocol among infertile poor responders

Purpose
Treatment

Inclusion/Exclusion criteria
Inclusion criteria:
three or fewer oocytes were been retrieved in previous failed ART cycle; serum E2 levels \leq 500 pg/ml on the day of hCG administration.

Exclusion criteria:
BMI >30 mg/m²; endocrine or metabolic disorders; history of ovarian surgery; severe endometriosis; azoospermia in male partner. FSH >15 m IU/ml

Age
From **20 years** old to **45 years** old

Gender
Female

Phase
2

Groups that have been masked
No information

Sample size
Target sample size: **200**
Actual sample size reached: **184**

Randomization (investigator's opinion)
Randomized

Randomization description
Randomization by table of random numbers

Blinding (investigator's opinion)
Not blinded

Blinding description

Placebo
Not used

Assignment
Parallel

Other design features

Secondary Ids
empty

Ethics committees

1
Ethics committee
Name of ethics committee
Ethics committee of Yazd Research and Clinical Center for infertility, Shahid Sadoughi University of
Street address
Bouali Ave, Safaeiyeh
City
Yazd

Province
Yazd
Postal code
8916877391

Approval date
2010-10-31, 1389/08/09
Ethics committee reference number
2311

Health conditions studied

1
Description of health condition studied
Infertility
ICD-10 code
N70-N77
ICD-10 code description
Inflammatory diseases of female pelvic organs

Primary outcomes

1
Description
chemical pregnancy
Timepoint
12 day after embryo transfer
Method of measurement
beta hCG blood test

2
Description
clinical pregnancy
Timepoint
3 weeks after chemical pregnancy
Method of measurement
observation of fetal heart activity by transvaginal ultrasonography

3
Description
implantation rate
Timepoint
3 weeks after chemical pregnancy
Method of measurement
the ratio of the number of embryonic sacs diagnosed by sonography to the total number of the embryos transferred

Secondary outcomes

empty

Intervention groups

1
Description
group I: clomiphen citrate 50 mg twice a day from 3th

day of menstruation cycle until 7th day of the cycle.

Category

Treatment - Drugs

2

Description

group II: letrozole 2.5 mg twice a day from 3th of the cycle until 8th day.

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Research and Clinical Center for Infertility

Full name of responsible person

Maryam Eftekhar

Street address

Bouali Ave

City

Yazd

Province

Yazd

Postal code

8916977443

Phone

+98 35 3824 7085

Email

eftekhar@ssu.ac.ir

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

shahid sadoughi university of medical science

Full name of responsible person

masood mirzaee

Street address

bahonar Ave

City

Yazd

Province

Yazd

Postal code

8916978477

Phone

+98 35 3726 3733

Email

masoud_mirzaei@hotmail.com

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

shahid sadoughi university of medical science

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Research and Clinical Center for Infertility

Full name of responsible person

Maryam Eftekhar

Position

Reserch faculty member

Latest degree

Medical doctor

Other areas of specialty/work

Gynecology and Obstetrics

Street address

Safaeiyeh, Bouali Ave

City

Yazd

Province

Yazd

Postal code

8916977443

Phone

+98 35 1824 7085

Fax

Email

eftekhar@ssu.ac.ir

Web page address

Person responsible for scientific inquiries

Contact

Name of organization / entity

Research and Clinical Center for Infertility

Full name of responsible person

Maryam Eftekhar

Position

Gynecologist/MD

Latest degree

Medical doctor

Other areas of specialty/work

Gynecology and Obstetrics

Street address

Safaeiyeh, Bouali Ave

City

Yazd

Province

Yazd

Postal code

8916877391

Phone
+98 35 1824 7085
Fax
Email
eftekhar@ssu.ac.ir
Web page address

Person responsible for updating data

Contact

Name of organization / entity
Yazd University of Medical Sciences
Full name of responsible person
Maryam eftekhar
Position
Professor
Latest degree
Medical doctor
Other areas of specialty/work
Gynecology and Obstetrics
Street address
Yazd Yazd Infertility Research Center, Bouali Street
City
Yazd
Province
Yazd
Postal code
8916977443
Phone
+98 35 3824 7085
Email
eftekhar@ssu.ac.ir

Deidentified Individual Participant Data Set (IPD)

Yes - There is a plan to make this available

Study Protocol

Yes - There is a plan to make this available

Statistical Analysis Plan

Yes - There is a plan to make this available

Informed Consent Form

Yes - There is a plan to make this available

Clinical Study Report

Yes - There is a plan to make this available

Analytic Code

Yes - There is a plan to make this available

Data Dictionary

Yes - There is a plan to make this available

Title and more details about the data/document

All participant data sets are to be shared

When the data will become available and for how long

2 months after the result publication

To whom data/document is available

A journal in which the results are published

Under which criteria data/document could be used

Submission of an official application via the agent that is legally in charge

From where data/document is obtainable

Yazd Reproductive Sciences Institute, Bouali Ave, Yazd, Iran

What processes are involved for a request to access data/document

Request from the Research Deputy, submitted to the Research Council of the Center if the request accepts its referral to the security and after completion of the relevant forms, the request is referred to the research experts and then get the data.

Comments

Sharing plan

Trial results

Please tick if results have been published

Yes

Summary result posting date

2021-03-07, 1399/12/17

Table of baseline comparison

Baseline characteristics of the patients in both groups

Variable	Clomiphene group (n=80)	Letrozole group (n=87)	p-values
Mean age (years)	37.37 ± 4.36	37.22 ± 3.95	0.807
BMI (kg/m ²)	24.56 ± 2.53	25.2 ± 2.34	0.099
Infertility duration (years)	9.17 ± 6.53	7.93 ± 4.70	0.169
Basal FSH level (mIU/mL)	8.95 ± 4.08	8.70 ± 4.20	0.705
Number of previous failed failing IVF/ICSI cycles	2.53 ± 1.12	2.16 ± 0.44	0.431
Duration of hormonal stimulation (days)	11.22 ± 1.39	11.35 ± 1.23	0.520
Total number of hMG ampoules (IU)	29.60 ± 9.07	29.27 ± 9.78	0.825
E ₂ level on the day of hCG (pg/mL)	978.46 ± 614.99	1131.83 ± 677.73	0.216

Endometrial thickness (mm)	8.39 ± 0.38	9.16 ± 1.24	0.000
Number of oocyte retrieved	3.97 ± 3.18	4.25 ± 2.84	0.553
Number of embryo obtained	2.50 ± 2.04	2.31 ± 1.10	0.452
Number of embryo transferred	2.01 ± 0.92	2.00 ± 0.83	0.927

Participant flow diagram

Table of variable outcomes' results

Outcome of IVF/ICSI-ET treatment cycles in both groups

Variable	Clomiphene group (n=80)	Letrozole group (n=87)	p-value
Fertilization rate (%)	58.74%	62.6%	0.482
Implantation rate (%)	6.6%	7.2%	0.024
Chemical pregnancy rate ^a n, (%)	10.87 (11.5%)	11.80 (13.8%)	0.816
Clinical pregnancy rate ^b n, (%)	7 (8%)	9 (11.3%)	0.601
Miscarriage rate ^c n, (%)	(30%)	(27.3%)	1.00

chi-square test was use.

P ≤0.05 was considered statistically significant

^a: Chemical pregnancy per cycle ^b: Clinical pregnancy per cycle ^c: Miscarriage rate per pregnancy

Table of adverse events

First publication date

2014-11-15, 1393/08/24

Abstract of published paper

Abstract Background: Poor ovarian response to controlled ovarian stimulation is one of the most important interest points in assisted reproduction. Mild ovarian stimulation seems to be preferable to high dose of FSH regimens in women with a history of poor ovarian response in previous protocol. Clomiphene citrate and letrozole alone or in combination with FSH have been used in mild ovarian stimulation protocol. Objective: To compare the efficacy of letrozole and clomiphene citrate for mild ovarian stimulation on assisted reproductive technology outcomes in poor responders. Materials and Methods: In a randomized control study, 184 women aged between 20 and 45 years with the history of poor response to ovarian stimulation who were candidate for ART were randomly subdivided into two groups: group I (n= 80), women who underwent the clomiphene/gonadotropin/antagonist protocol; and group II (n= 87), patients who underwent the letrozole/gonadotropin/antagonist protocol. Groups were compared regarding implantation, chemical and clinical pregnancy rates. Results: There was a significant difference in the mean endometrial thickness between two groups (9.16±1.2 mm vs. 8.3±0.3 mm). The implantation rate was significantly higher in letrozole group compare to clomiphene group (7.2 vs. 6.6%, p=0.024 respectively). No significant differences were found in chemical and clinical pregnancy rate between two groups. Conclusion: In mild ovarian stimulation protocol, letrozole and clomiphene have similar value for the poor responder. The optimal treatment strategy for these patients remains debated.